Theravance's Q4 Earnings and Revenues Miss Estimates [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company had incurred an adjusted loss of 5 cents per share. Total revenues in the quarter were $45.9 million, which missed the Zacks Consensus Estimate of $60 million. Revenues surged 145% year over year, driven primarily by $25 million of licensing and milestone revenues from partner Viatris VTRS tied to Yupelri (revefenacin) sales in the United States. Year to date, shares of Theravance have lost 25.1% compared with the industry's 3.1% decline. Zacks Investment Research Image Source: Zacks Investment Research TBPH's Q4 Earnings in Detail The company's top line consisted of collaboration revenues, along with licensing and milestone revenues tied to Viatris' Yupelri sales in the reported quarter. Collaboration revenues amounted to $20.8 million, up 11.4% year over year. The company also recorded $25 million in licensing and milestone revenues associated with Yupelri sales. Theravance and VTRS have collaborated on the development and commerc
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026 [Yahoo! Finance]Yahoo! Finance
- Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Viatris Stock: Is VTRS Outperforming the Health Care Sector? [Yahoo! Finance]Yahoo! Finance
- Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) [Yahoo! Finance]Yahoo! Finance
- Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)PR Newswire
VTRS
Earnings
- 2/26/26 - Beat
VTRS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/24/26 - Form 4
- 3/23/26 - Form 144
- VTRS's page on the SEC website